U.S. pharma giant copyright scrapped two experimental weight loss tablets last calendar year—a as soon as-everyday pill, lotiglipron, because of elevated liver enzymes and a twice-daily tablet, danuglipron, resulting from solid Unintended effects—but CEO Albert Bourla has reported the company is determined to “Engage in and get” while in th… Read More